AN2 Therapeutics, Inc.
AN2 Therapeutics (Nasdaq: ANTX) is a clinical-stage biopharmaceutical company discovering and developing small-molecule therapeutics using its boron chemistry platform. Its pipeline addresses hematologic diseases, infectious diseases and oncology, with clinical programs including epetraborole for polycythemia vera and… From the company’s description.
In fiscal 2025, AN2 Therapeutics, Inc. reported a net loss of $35.17M. Operations used $29.83M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What AN2 Therapeutics, Inc. does
In the company’s own words
AN2 Therapeutics (Nasdaq: ANTX) is a clinical-stage biopharmaceutical company discovering and developing small-molecule therapeutics using its boron chemistry platform. Its pipeline addresses hematologic diseases, infectious diseases and oncology, with clinical programs including epetraborole for polycythemia vera and Mycobacterium abscessus complex lung disease, and AN2-502998 for Chagas disease. Research programs include preclinical candidates targeting PI3Kα and ENPP1 in oncology, as well as work in bone disorders and infectious diseases. The company’s global health programs include melioidosis and tuberculosis, supported primarily by grants and partnerships. AN2 licenses epetraborole in China, Hong Kong, Taiwan and Macau to Brii Biosciences, which is responsible for development and commercialization in those territories. The company relies on third-party manufacturers for materials and drug products used in preclinical studies and clinical trials. It was founded around a boron-based drug discovery approach, with licensed compounds and intellectual property underpinning its development programs. Its website is https://www.an2therapeutics.com/.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- MENLO PARK, CA
- Fiscal year end
- December
- CIK
- 1880438
- SIC
- 2834
Financial performance, year by year
Fiscal 2022–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns AN2 Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · AN2 Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do AN2 Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of AN2 Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in AN2 Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”